In Silico Study: Combination of α-Mangostin and Chitosan Conjugated with Trastuzumab against Human Epidermal Growth Factor Receptor 2

In Silico Study: Combination of α-Mangostin and Chitosan Conjugated with Trastuzumab against Human Epidermal Growth Factor Receptor 2

Breast cancer is a type of cancer with the highest prevalence worldwide. Almost 10–30% of breast cancer cases are diagnosed as positive for HER2 (human epidermal growth factor receptor 2). The currently available treatment methods still exhibit many shortcomings such as a high incidence of side effe...

Full description

Bibliographic Details
Main Authors: Sandra Megantara, Nasrul Wathoni, Ahmed Fouad Abdelwahab Mohammed, Cecep Suhandi, Maryam H. Ishmatullah, Melisa F. F. D. Putri
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Polymers
Subjects:
breast cancer
α-mangostin
trastuzumab
HER2
in silico
FireDock
Online Access:https://www.mdpi.com/2073-4360/14/13/2747

Similar Items

Similar Items